Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial
- DOI
- 10.1016/j.ejca.2026.116730
- Published
- 2026-06
- Container
- European Journal of Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejca.2026.116730,
title = {Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial},
author = {Bertrand Tombal and Maha Hussain and Fred Saad and Karim Fizazi and Neal Shore and Evgeny Kopyltsov and Martin Bögemann and Maria J. Mendez-Vidal and Natasha Littleton and Shankar Srinivasan and Frank Verholen and Matthew R. Smith},
year = {2026},
journal = {European Journal of Cancer},
doi = {10.1016/j.ejca.2026.116730},
url = {https://doi.org/10.1016/j.ejca.2026.116730}
}RIS
TY - JOUR TI - Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial AU - Bertrand Tombal AU - Maha Hussain AU - Fred Saad AU - Karim Fizazi AU - Neal Shore AU - Evgeny Kopyltsov AU - Martin Bögemann AU - Maria J. Mendez-Vidal AU - Natasha Littleton AU - Shankar Srinivasan AU - Frank Verholen AU - Matthew R. Smith PY - 2026 JO - European Journal of Cancer DO - 10.1016/j.ejca.2026.116730 UR - https://doi.org/10.1016/j.ejca.2026.116730 ER -
APA
Tombal, B., Hussain, M., Saad, F., Fizazi, K., Shore, N., Kopyltsov, E., Bögemann, M., Mendez-Vidal, M. J., Littleton, N., Srinivasan, S., Verholen, F., & Smith, M. R. (2026). Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116730
Source records
- crossref · retrieved 2026-09-26T16:46:35.314Z